Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pacer has an update posted yesterday on the Coulter et al. case that's in mediation. Anyone have access to the document?
I don't think they needed to do that in 2020. They filed on August 14th and their market cap was much higher that year.
Been through this before. SEC told them they weren't large accelerated.
Shorts were up over 2 million before July 15th. They've been eating through all available shares ever since. I know Fidelity charges a minimum of $1 per share for short borrowing. The .25% lending fee doesn't look like much, but if they all do it at $2/share, the shorts could be in for sticker shock come Monday. We'll find out next week......
What he actually did get was a cheaper price for the warrants - .20 vs .30
You mean immediately exercisable warrants that can be used to pay bills for Cytodyn and can be exchanged for cash or shares in a buy out? What would happen to warrants that couldn't be exchanged for shares prior to a buy out?
Teepan says the borrow rate is now 41%. That's 60k a day and climbing for 53 million shares. No shares have been available since the end of the day Thursday.
No one's listening to Mr. Whipple
OTC share count went up last night by 59 million. If that was warrants and they were around.40, that's 20 million raised.
Oh, and form 4 came out yesterday.
Company coming up current on filings. Is this a real company or a shell? Seen some nice reverse mergers on OTC
The previous CEO had shares convertible to a little over 2 billion. They may have just bought him out. I think most of the convertible debt was already accounted for.
It was always back burnered. Paul was more interested in cancer. Joe Stavola was a huge proponent, but he and his wife died in the Merritt Parkway when a tree fell on their car. After that, nothing much was done with it until Cytodyn bought it.
Before that, much wasn't done either. The guy I inherited the phase 1 study from hadn't even reviewed trip reports for over a year. The guy who monitored the study said he had a fire in his office and all his original reports got destroyed. When I asked him to make some updates, he refused. No one forced him to do it because he was independent, so I had to file his hard copy reports with my comments.
That's how little was put into the drug before NP championed it. I bought into Cytodyn because of how much the drug meant to Joe.
They have other parents to cover them. But, does this mean that if they don't get approval until after February 2023 they won't owe licensing fees to Progenics (and possibly Abbvie?)
Don't know if it's a typo or not, buy YMB has us at 9.75% insider and .7% institution owned. Even if you go by YMB's outstanding shares, that puts us at over 70 million. Who bought all those shares?
It's 78%. They created a new share type for the new guys. The old guy mostly has shares to convert to common shares - 2.02 billion. None of them have any value other than conversion. They post form 3s back in June. I think that covers them for disclosure.. I saw something on Twitter I believe that the merger closed on June 29th. Look through some old financials for the original company. They acquired some businesses but didn't do much with them. They have the full agreement attached to the 8k from May 4th
Any intellectual property goes to Cytodyn. Doesn't matter who gets the check. It's just the government sending the investigator the money instead of Cytodyn.
And, yet, they didn't feel the need for an emergency meeting in July. The date of the meeting is actually close to when they originally set their regular meeting for last year. It begs the question - why not just have a regular annual meeting a little early? They have 2 open board positions. Why not just fill them and get it over with? Paulson's invested heavily now. I don't think they'd put anyone up that he wouldn't go along with. They have the new president starting today. If there was a push to evict Scott Kelly, he has 4 million shares. He could kick back and watch the share price go up.
And, you gloss over the part where it says the shares could be used for an acquisition. They need the other language there to tamp down enthusiasm because nothing is ever guaranteed and they might end up alone. they have to remind people that this is a possibility
They made sure to specify that the shares could be used for acquisition or partnership and wouldn't be used as a poison pill to avoid a takeover that may be beneficial to stockholders
They were awarded $5 million for the new grant. It doesn't matter anyway. The money goes to Oregon. They don't need anything from Cytodyn. If they come up with anything, Cytodyn gets the patent. I think the grant may also cover a Phase 0 or 1 study in humans. No one expects that to happen within a year.
Total award vs. annual distribution.
1.4 million short shares -68% of all trades - borrow rate went up to 23% at one point today - all but 2l shares borrowed (enough to keep an eye on the borrow rate. All that happened was that you had to go to the third decimal place to say the price dropped to the thirties and you have to pay an extra percentage point on all 52 million outstanding short shares over a 3 day weekend in order to hit a pretend psychological wall that longs weren't even thinking about.
Clinical databases are slightly different. A better comparison may be Chinese dialects. You can communicate well enough in person, but when you try to write things down, it may not translate because the symbol you chose for one dialect isn't discernable by someone using a different dialect and you are left with no idea of what symbol you would choose. You know something is being said, but you don't know what. All of that gets left in translation. You don't even know it's a problem unless someone tells you it is. That's normally a CRA or data manager and it shows up through the query process. This is standard practice in the industry and, most likely, a completely foreign concept to FDA reviewers who take a hands off approach to database auditing and use forms and reports for their findings. If they had added a query process, it could have gone back to data management and a worker bee somewhere would have figured out the problem - most likely because their metrics depended on it and no one wants to go into their annual review with bad metrics.
My suggestion would be to ask the FDA to print off an electronic copy of the CRFs (or whatever they call the visual aspect of the database), send it to the company after it's been confirmed as received and uploaded and wait for a validation before moving forward with the formal review. It would add a step, but alleviate frustration and wasted time on the part of the FDA.
You could have something as simple as a field that says "Adverse Event" that is matching up to a field that says "Adverse event" on the FDA side and I f you didn't program the transfer correctly, the data would never get pushed though to the recipient. That could happen for an original programming or even an update to o the system.
The other thing that would be nice is a validation screen shot of what the FDA is seeing so the pharma can make sure it all came through properly.
In all honesty, the FDA should have a sandbox available to programmers and developers so they can see how the data transfer will work and how it will look to the reviewer so that internal auditors at pharma can do a final check before submission
FDA changed how they would take submissions. They refused to take paper and would only take electronic. Amarex's website said they were ready for this change, but they must not have been. No sabotage. Just stubbornness and clash of personalities. Hopefully, the new CRO has a database that they know works with the FDA system. The reviewer even said that they could see the AEs in the data transfer files, but it wasn't populating into their database for review.
The worst that happens is that they do double data entry inhouse into a database like EPIC, do their validation of the data transfer and send a bill to Amarex.
Wrong format just means they don't have it as SAS transport files or whatever is currently being used and the accepted computer language for data transfer. It's like they submitted the data in German instead of English. Now they're translating to English so it can be backtranslated to whatever language the particular agency or company speaks. A pain in the butt to do and validate, but once you're done, you're done
50+% of trades have been pretty consistently short. Spikes in new investors have happened after conferences. No one is making decisions based on our hopes and dreams.
They say it's because of the way it "fills up" the spaces on the cell membranes. I say that the 709 mg group got one less dose because of placebo run in and 14 weeks is just on the cusp of activity. I also just remembered that the 350 mg group needed a biopsy. Patients hate those. It makes it hard to recruit. They may have just gotten a more cohesive group because of the state of the disease necessary to agree to that.
She' has patients on the drug. That means she has CRAs visiting regularly for data review. They aren't privy to insider information, but they can learn things from the course of business. When Cytodyn bought Pro-140, they had someone audit the files. They had findings they wanted addressed. Progenics contacted me because I'd been on the study. I didn't know who was buying Pro-140, but I knew it was being sold.
All the talk of failed studies on this platform because of phase 2 endpoints not being met. Check out ILC. 2022 on Twitter now to see how actual doctors respond to study results when a primary endpoint isn't met but they're still encouraged by the response. They actually got a late breaker spot for a "failed" trial
That Thanks to Chuckles was supposed to be a smiley face with heart eyes. I guess you can't emojie here. Sorry
Thanks??
9:30 am is the poster presentation. He has a second one. It was added late. May be the noon walk through with the experts, but I can't say that for sure. There is a noon walk through with experts, but I didn't see where they listed the specific posters being reviewed. We would be a late breaker on that if so.
Again, your assumption was incompetence. Form 8k from 5/31 shows that they quite competently withheld payroll taxes when providing shares in lieu of salary
And you can block out all reason. Why would HR know to do it for him and the CFO state in their 8k that they are doing it and then not do it for the others? Your assumption was that they were too incompetent to know that they had to withhold taxes. The 8k shows that assumption is incorrect.
The 5/31 8k awarding shares in lieu of salary to a former executive less appropriate payroll taxes etc.
I'm sure you guys are going to want to say that's for NP and doesn't mean they took it out for the others. I believe their HR department is competent enough to know to do it for all since they obviously know to take them out.
Read the 8k. They took out taxes
They took out regular taxes for the salary, so I would think they need an expert accountant this year if we get a cash offer.
Yep. Same with letting someone exercise warrants for $1 even if they currently end up underwater. If they can't buy at the market, at least they can put a few bucks in the coffers now and will get their payday later
Isn't that the one where the SEC weirdly said the FDA wouldn't be happy with Cytodyn saying leronlimab worked in it's quarterly filings because they hadn't gotten the drug approved yet? They addressed that although, technically, they were within their rights to report their interpretation of the outcome of the study. They weren't making false claims about efficacy to patients. That stuff was used to take down some hemp gummy websites. It was dumb to try to apply it to leronlimab
It was probably just the Fife thing that got resolved in March